19th March 2020: The Next Generation Sequencing (NGS) market is expected to grow due to high demand for precision treatment, genomics research, and clinical diagnosis of varied diseases. NSG enables rapid sequencing of the base pairs in RNA or DNA samples. It is also used for various applications, such as chromosome counting, gene expression profiling, molecular analysis, and detection of epigenetic changes and has enabled innovation and discovery in personalized medicine.
NSG Services promote treatment and diagnosis of rare diseases
Based on products and services the NGS platforms and products accounted for the largest share of the market in 2018. The segment comprises of software and instruments that are used for preparation of samples, libraries, and sequencing. The most widely used NGS products include Illumina’s MiniSeq, MiSeq, and NextSeq, Thermo Fisher’s Ion Proton System, Ion PGM, and Ion GeneStudio S5 NGS system. MiniSeq, offers cost-efficient sequencing, streamlined workflow enabling sequencing, and ancillary equipment and provides scientists and engineers with training, and support, through data analysis.
On the other hand, the NGS services segment is anticipating growth during the forecast period (2019 - 2025). Key companies such as Roche; Illumina, Inc.; and Pacific Biosciences, offer various services to assist the researchers and promote development personalized medicines, genomic sequences, and in the diagnosis of rare diseases.
Market insight
Increasing applications of NGS along with its affordable cost and accuracy with other advantages such as drug discovery are likely to boost the growth of the market. The development of personalized medicine offers new scope accelerating the market growth. Difficulty of data handling and other issues associated with Big Data management are concerns that hamper the growth of the market.
Biotech industries are making investments in order to cure diseases using the NGS to develop advanced diagnostic kits. Major companies of the market are also keen on promoting new product development initiatives along other strategies such as M&A to strengthen their position in the market. For instance, Edico Genome was acquired by Illumina to improve the overall efficiency of NGS solutions. Key companies in the next generation sequencing (NSG) market include Eurofins GATC Biotech GmbH; Oxford Nanopore Technologies; Thermo Fisher Scientific, Inc.; BGI; PierianDx, Inc.; Perkin Elmer, Inc.; F Hoffman-La Roche Ltd.; Genomatix GmbH; Illumina Inc.; DNASTAR, Inc.; QIAGEN; and Bio-Rad Laboratories, Inc.
No comments:
Post a Comment